The MAGPIE trial conclusively demonstrated that magnesium sulphate, compared to placebo, in women with pre-eclampsia reduces the risk of which of the following outcomes?
- A Maternal death by 40%
- B Eclampsia by approximately 58% ✓
- C Perinatal mortality by 25%
- D Recurrence of hypertension postpartum
Correct answer: B. Eclampsia by approximately 58%
Explanation
The MAGPIE trial (2002) randomised 10,141 women with pre-eclampsia to magnesium sulphate vs placebo and showed a 58% reduction in the risk of eclampsia in the magnesium group. There was no statistically significant reduction in maternal mortality or perinatal mortality. Magnesium sulphate is now the anticonvulsant of choice for both prophylaxis and treatment of eclampsia in women with severe pre-eclampsia.
Reference: Williams Obstetrics, 26th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.